Previous 10 | Next 10 |
home / stock / ucbjy / ucbjy news
2023-10-18 10:49:13 ET More on UCB SA Seeking Alpha’s Quant Rating on UCB SA Historical earnings data for UCB SA Dividend scorecard for UCB SA Financial information for UCB SA For further details see: FDA approves UCB's Bimzelx for plaque p...
BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis PR Newswire BIMZELX ® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate-to-severe plaque p...
UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis PR Newswire FDA approval of ZILBRYSQ ® (zilucoplan) has been granted for the treatment of generalized myasthenia gravis (gMG) in adult pa...
UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023 PR Newswire Results from the Phase 3 studies evaluating impact of bimekizumab on pain and health-related quality of life in moderate-to-severe hidradenitis suppurativa will ...
Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa PR Newswire Bimekizumab treatment resulted in clinically meaningful improvements in HiSCR50 and the more stringent endpoints HiSCR75, HiSCR...
2023-09-15 11:05:45 ET More on Lilly, Ascendis, and Novartis Eli Lilly: A Potential Game Changer For Weight Management And Cardiovascular Health Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge Sandoz to commercialize biosimilar to J&J blockbuster drug ...
UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. PR Newswire RYSTIGGO...
UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis PR Newswire FDA approval of RYSTIGGO ® (rozanolixizumab-noli) has been granted under the Priority Review designation for the treat...
2023-06-05 05:02:09 ET Summary ClearPoint Neuro's progress on its four-pillar strategy continues despite a challenging operating environment, with an increasing number of partners and hospital sites featuring its equipment. The company has entered into pre-clinical work and milest...
UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting PR Newswire New insights from leading portfolio demonstrate ongoing commitment to improving outcomes and experiences of those living with epilepsy and rare epilep...
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting PR Newswire Diverse and patient-focused data set comprises 17 abstracts including one oral presentation Features new data analyse...
UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa PR Newswire Campaign offers resources and information about hidradenitis suppurativa (HS) and amplifies diverse patient voices and stories to reach p...
FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations PR Newswire Application in moderate-to-severe hidradenitis suppurativa based on results from two...